EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers - CRCL-OncoPharmacologie
Article Dans Une Revue npj Precision Oncology Année : 2024

EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers

Marie Morfouace
  • Fonction : Auteur
Charalambos Loizides
  • Fonction : Auteur
Julio Oliveira
  • Fonction : Auteur
Laurent Greillier
Judith Raimbourg
  • Fonction : Auteur
Thierry Chatellier
  • Fonction : Auteur
Nicolas Cloarec
  • Fonction : Auteur
Ivana Sullivan
Kersti Oselin
  • Fonction : Auteur
Marie-Sophie Robert
  • Fonction : Auteur
Carolina Fernandes
  • Fonction : Auteur
Arnaud Poncin
  • Fonction : Auteur
Jean-Yves Blay
Benjamin Besse
  • Fonction : Auteur
Nicolas Girard
  • Fonction : Auteur

Résumé

Arcagen (NCT02834884) is a European prospective study aiming at defining the molecular landscape of rare cancers for treatment guidance. We present data from the cohort of rare thoracic tumors. Patients with advanced pleural mesothelioma (PM) or thymic epithelial tumors (TET) underwent genomic profiling with large targeted assay [>300 genes, tumor mutational burden (TMB), microsatellite instability (MSI) status] on formalin-fixed paraffin-embedded (FFPE) or plasma samples. EORTC molecular tumor board (MTB) advised for biomarker-guided treatments. 102 patients recruited from 8 countries between July 2019 and May 2022 were evaluable: 56 with PM, 46 with TET (23 thymomas, 23 thymic carcinomas). Molecular profiling was performed on 70 FFPE samples (42 PM, 28 TET), and 32 cases on ctDNA (14 PM, 18 TET), within a median turnaround time of 8 days from sample reception. We detected relevant molecular alterations in 66 out of 102 patients (65%; 79% PM, 48% TET), 51 of 70 FFPE samples (73%; 90% PM, 46% TET), and 15 of 32 plasma samples (47%; 43% PM, 50% TET). The most frequently altered genes were CDKN2A/B, BAP1, MTAP in PM and TP53, CDKN2A/B, SETD2 in TET. The TMB was low (mean 3.2 Muts/MB), 2 PM had MSI-high status. MTB advised molecularguided treatment options in 32 situations, for 17 PM and 15 TET patients (75% clinical trial option, 22% off-label drug or compassionate use, 3% early access program). Molecular testing and MTB discussion were feasible for patients with rare thoracic cancers and allowed the broadening of treatment options for 30% of the cases.

Domaines

Cancer
Fichier principal
Vignette du fichier
41698_2024_Article_518.pdf (935.9 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04728457 , version 1 (09-10-2024)

Identifiants

Citer

Marco Tagliamento, Marie Morfouace, Charalambos Loizides, Julio Oliveira, Laurent Greillier, et al.. EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers. npj Precision Oncology, 2024, 8, ⟨10.1038/s41698-024-00518-9⟩. ⟨hal-04728457⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More